Media coverage about Agile Therapeutics (NASDAQ:AGRX) has trended positive on Sunday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Agile Therapeutics earned a news sentiment score of 0.25 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 46.6719901247479 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

A number of analysts recently commented on the company. HC Wainwright set a $8.00 price target on Agile Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 28th. Noble Financial reaffirmed a “buy” rating on shares of Agile Therapeutics in a research report on Thursday, December 28th. Janney Montgomery Scott downgraded Agile Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 28th. William Blair downgraded Agile Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 26th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $5.00 price target on shares of Agile Therapeutics in a research report on Friday, December 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $9.20.

Agile Therapeutics (NASDAQ:AGRX) traded up $0.07 during trading hours on Friday, reaching $3.39. The company’s stock had a trading volume of 99,200 shares, compared to its average volume of 910,108. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.14. Agile Therapeutics has a twelve month low of $1.93 and a twelve month high of $5.60. The stock has a market capitalization of $118.34, a P/E ratio of -3.68 and a beta of 2.00.

Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.03. analysts forecast that Agile Therapeutics will post -0.97 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/28/agile-therapeutics-agrx-earning-favorable-news-coverage-analysis-finds.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Insider Buying and Selling by Quarter for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.